Low affinity FcγR deficient mice
Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.
1. A transgenic mouse whose genome comprises a homozygous disruption in an endogenous FcγRIIB α-chain gene, a homozygous disruption in an endogenous FcγRIV α-chain gene, and a homozygous disruption in an endogenous FcγRIII α-chain gene.
2. The mouse of claim 1 , wherein the mouse comprises a reduced ability to make an immune response to an antigen as compared to a wild-type mouse with respect to the same antigen.
3. The mouse of claim 1 , wherein the mouse comprises at least a 50% reduction in antibody-dependent cell-mediated cytotoxicity (ADCC).
4. The mouse of claim 1 , wherein the mouse comprises a functional FcR γ-chain.
5. A genetically modified mouse cell whose genome comprises a homozygous disruption of an endogenous FcγRIIB α-chain gene, a homozygous disruption of an endogenous FcγRIV α-chain gene, and a homozygous disruption of an endogenous FcγRIII α-chain gene.
6. The cell of claim 5 , wherein the cell comprises a functional FcR γ-chain.
7. The cell of claim 5 , wherein the cell is an embryonic stem (ES) cell.
8. A method of making a genetically modified mouse that does not express an endogenous FcγRIIB α-chain, an endogenous FcγRIV α-chain, and an endogenous FcγRIII α-chain, comprising using the cell of claim 7 .
9. The cell of claim 5 , wherein the cell is a natural killer (NK) cell.